Skip to main content
David Steensma, MD, Oncology, Cambridge, MA

DavidPSteensmaMDFACP

Oncology • Cambridge, MA

Hematologic Oncology

Global Head of Hematology, Novartis Institutes for BioMedical Research

Join to view full profile

Dr. Steensma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Steensma's full profile

Already have an account?

Education & Training

  • University of Oxford
    University of OxfordNA, Molecular Hematology, 2002 - 2004
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1999 - 2002
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1996 - 1999
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1996
  • Calvin University
    Calvin UniversityBS, Physics & Astronomy, 1988 - 1992

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2009 - 2024
  • FL State Medical License
    FL State Medical License 2016 - 2018
  • MN State Medical License
    MN State Medical License 1997 - 2009
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor or National Top Doctor Castle Connolly
  • Boston Magazine Top Doctors - Medical Oncology, 2017
  • Leadership in Science Aplastic Anemia & MDS International Foundation, 2016
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk Factor  
    Robert Sidlow, Amy E Lin, David P Steensma, Benjamin L Ebert, JAMA Cardiology
  • The Phenotypic Spectrum of Germline YARS2 Variants: From Isolated Sideroblastic Anemia to Mitochondrial Myopathy, Lactic Acidosis and Sideroblastic Anemia 2  
    Matthew M Heeney, Gregory A Hale, David P Steensma, Mark D Fleming, Colin A Sieff, Lee M Hilliard, Sylvia S Bottomley, Janet L Kwiatkowski, Haematologica

Abstracts/Posters

  • Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
    David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
    David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
    David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • How to Interpret Next Generation Sequencing Panels in Patients with CHIP and Hematolymphoid Neoplasms 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • The Molecular Maelstrom of Myelodysplastic Syndromes (MDS) 
    60th American Society of Hematology Annual Meeting - 12/2/2018
  • Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Other

Authored Content

  • Editor’s Corner: The Zoombie ApocalypseJuly 2020
  • The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk FactorMay 2020

Press Mentions

  • Unfiltered: The Insurance Denials Most Frustrating to Physicians
    Unfiltered: The Insurance Denials Most Frustrating to PhysiciansApril 21st, 2023
  • ASH Minority Recruitment Initiative Seeks Mentors, ASH Joins in Support of the Federal Safe Step Act, and More
    ASH Minority Recruitment Initiative Seeks Mentors, ASH Joins in Support of the Federal Safe Step Act, and MoreJune 2nd, 2021
  • End of an Era: The Medical Community Responds to the Elimination of Step 2 CS
    End of an Era: The Medical Community Responds to the Elimination of Step 2 CSFebruary 3rd, 2021
  • Join now to see all

Grant Support

  • Edward P. Evans Center for Myelodysplastic Syndromes at Dana-FarberEdward P. Evans Foundation2019–2024
  • Pathogenesis of Myeloid NeoplasiaJames and Lois Champy Foundation2015–Present
  • MDS Clinical Research ConsortiumEdward P. Evans Foundation - AA&MDS IF2012–Present
  • SPORE in Myeloid MalignanciesNational Cancer Institute2017–2022
  • Targeting Stem Cells in Acute LeukemiasV Foundation2013–2018

Committees

  • Member, American Society of Hematology Committee on Publications 2017 - Present
  • Scientific Advisory Board / Grant Reviewer, Joseph P. Dresner Foundation 2016 - Present
  • Member, American Board of Internal Medicine Hematology Examination Committee 2016 - Present
  • Scientific Advisory Board / Grant Reviewer, Edward P. Evans Foundation 2015 - Present
  • Member, American Society of Hematology Task Force on Precision Medicine 2015 - Present
  • Member, American Society of Hematology Committee on Educational Affairs 2013 - Present
  • Board of Directors, Myelodysplastic Syndromes Foundation 2009 - 2013
  • Oncology Drugs Advisory Committee, Food and Drug Administration 2007 - 2012
  • Medical Advisory Board, Aplastic Anemia & Myelodysplastic Syndromes International Foundation

Professional Memberships

Other Languages

  • Dutch, German

Dr. David Steensma, Dr. David Steensma, MD, Dr. D Steensma, Dr. David P Steensma